

## 2 Months

Study	Country	Design		VE (95% CI)		
Patalon et al. (48)	Israel	TN	<b>—</b>	0.86 (0.85, 0.87)		
Lin et al. (24) (Sep-Nov '21)	USA	С	<b>⊨</b>	0.48 (0.47, 0.49)		
Andrews et al. (67) (age 19-49)	UK	TN	<b>I</b> ■I	0.78 (0.76, 0.79)		
Andrews et al. (67) (age 50+)	UK	TN	<b>■</b>	0.82 (0.81, 0.83)		
Hulme et al. (75)	UK	MC	i≡l .	0.53 (0.52, 0.54)		
Patalon et al. (49)	Israel	MTN	<b>⊢</b> ■I	0.43 (0.38, 0.48)		
Florea et al. (79)	USA	MC	HeH	0.54 (0.52, 0.56)		
Ranzani et al. (40)	Brazil	MTN	<b>=</b>	0.34 (0.33, 0.35)		
Stirrup et al. (86)	UK	С	<b>├──</b>	0.72 (0.62, 0.80)		
Ng et al. (76)	Singapore	С	H <del>=1</del>	0.32 (0.30, 0.33)		
Ng et al. (76)	Singapore	С	<b>⊢=</b> -1	0.07 (0.03, 0.12)		
Gonzalez et al. (80)	Argentina	MTN	Hel	0.19 (0.17, 0.20)		
Laake et al. (81)	Norway	С	H <del>=</del> H	0.37 (0.35, 0.39)		
Lind et al. (27)	USA	TN	<b>├</b>	0.55 (0.48, 0.61)		
Lin et al. (24) (Jan-Jun '22)	USA	С	H■H	0.36 (0.34, 0.39)		
			0 0.25 0.5 0.75 1			
Vaccine Effectiveness (VE)						

## 3 Months

Study	Country	Design			VE (95% CI)
Lin et al. (24) (Sep-Nov '21)	USA	С		H .	0.39 (0.38, 0.40)
Andrews et al. (67) (age 19-49)	UK	TN		<b>├──</b>	0.78 (0.66, 0.86)
Andrews et al. (67) (age 50+)	UK	TN		<del></del>	0.82 (0.71, 0.89)
Patalon et al. (49)	Israel	MTN		H <del>■</del> H	0.29 (0.26, 0.32)
Florea et al. (79)	USA	MC		<del></del>	0.30 (0.21, 0.39)
Ranzani et al. (40)	Brazil	MTN		<b>*</b>	0.25 (0.24, 0.25)
Stirrup et al. (86)	UK	С		<b>├──</b>	0.69 (0.60, 0.76)
Gonzalez et al. (80)	Argentina	MTN	<b>⊢</b>		-0.04 (-0.06, -0.01)
Laake et al. (81)	Norway	С		H <del>= I</del>	0.33 (0.30, 0.35)
Lind et al. (27)	USA	TN		<b>⊢</b>	0.44 (0.34, 0.53)
Lin et al. (24) (Jan-Jun '22)	USA	С		H■H	0.16 (0.14, 0.19)
			Γ		
			0	0.25 0.5 0.75 Vaccine Effectiveness (VE)	1